JP2024016209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016209A5 JP2024016209A5 JP2023191381A JP2023191381A JP2024016209A5 JP 2024016209 A5 JP2024016209 A5 JP 2024016209A5 JP 2023191381 A JP2023191381 A JP 2023191381A JP 2023191381 A JP2023191381 A JP 2023191381A JP 2024016209 A5 JP2024016209 A5 JP 2024016209A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- ctla
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| US63/023,554 | 2020-05-12 | ||
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
| JP2022554243A JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Division JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016209A JP2024016209A (ja) | 2024-02-06 |
| JP2024016209A5 true JP2024016209A5 (https=) | 2024-05-08 |
Family
ID=75977756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210355224A1 (https=) |
| EP (1) | EP4021940A1 (https=) |
| JP (2) | JP7387912B2 (https=) |
| KR (1) | KR20230009354A (https=) |
| CN (1) | CN114729054A (https=) |
| AU (3) | AU2021269832B2 (https=) |
| BR (1) | BR112022021893A2 (https=) |
| CA (1) | CA3158607A1 (https=) |
| IL (2) | IL311936A (https=) |
| MX (1) | MX2022006728A (https=) |
| TW (2) | TWI870592B (https=) |
| WO (1) | WO2021228978A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260077026A1 (en) * | 2022-09-07 | 2026-03-19 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| WO2025256641A1 (zh) * | 2024-06-13 | 2025-12-18 | 江苏恒瑞医药股份有限公司 | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| CA2484052C (en) | 2002-04-11 | 2011-06-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
| US7135180B2 (en) | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| WO2003086443A1 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| EP3277318A1 (en) * | 2015-04-01 | 2018-02-07 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| KR102664891B1 (ko) * | 2016-06-20 | 2024-05-13 | 에프-스타 테라퓨틱스 리미티드 | Pd-l1 및 lag-3에 결합하는 결합 분자 |
| MX2019003569A (es) * | 2016-09-27 | 2020-07-22 | Oncologie Inc | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. |
| JP2020515637A (ja) * | 2017-04-03 | 2020-05-28 | オンコロジー、インコーポレイテッド | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 |
| RU2019138742A (ru) * | 2017-05-26 | 2021-06-28 | Бруин Байосаенсис, Инк. | Средства для химиоэмболизации |
| JP2020522486A (ja) * | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| WO2019241742A1 (en) * | 2018-06-14 | 2019-12-19 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| AU2019285344A1 (en) * | 2018-06-15 | 2020-12-10 | Mina Therapeutics Limited | Combination therapies comprising C/EBP alpha saRNA |
-
2021
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko not_active Ceased
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en not_active Ceased
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt unknown
- 2021-05-12 TW TW110117153A patent/TWI870592B/zh active
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 TW TW114101922A patent/TW202535468A/zh unknown
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 IL IL297640A patent/IL297640A/en unknown
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
- 2021-05-12 AU AU2021269832A patent/AU2021269832B2/en active Active
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-03-28 US US18/620,387 patent/US20240239893A1/en active Pending
- 2024-05-03 AU AU2024202963A patent/AU2024202963B2/en active Active
- 2024-11-28 AU AU2024266949A patent/AU2024266949A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016209A5 (https=) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2007515469A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2017031160A5 (https=) | ||
| JP2009518441A5 (https=) | ||
| RU2018146812A (ru) | Фармацевтические комбинации | |
| JP2018522028A5 (https=) | ||
| JP2021509395A5 (https=) | ||
| JP2017537927A5 (https=) | ||
| JPWO2019241442A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2021511344A5 (https=) | ||
| JP2022501332A5 (https=) | ||
| JPWO2021123996A5 (https=) | ||
| JPWO2022256500A5 (https=) | ||
| JPWO2021228978A5 (https=) | ||
| JP2018522881A5 (https=) | ||
| JPWO2020223702A5 (https=) | ||
| JPWO2021180821A5 (https=) | ||
| JPWO2020159822A5 (https=) | ||
| Kaul et al. | Review on pulse therapy: a novel approach in the treatment of pemphigus vulgaris | |
| JPWO2019144098A5 (https=) |